Relmada Therapeutics Inc. (RLMD) 2.9900 $RLMD
Relmada Therapeutics hires Michael Becker as SVP of finance and corporate development to broaden and strengthen its senior leadership team
M2 - Wed Nov 05, 6:31AM CST
Biopharmaceutical company Relmada Therapeutics (OtherOTC:RLMD) disclosed on Tuesday the election of Michael D. Becker as senior vice president of its finance and corporate development with immediate effect.
Relmada Therapeutics Appoints Michael Becker As Senior Vice President Of Finance And Corporate Development
PR Newswire - Tue Nov 04, 7:00AM CST
Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Michael D. Becker as senior vice president of finance and corporate development, effective immediately.
Relmada Therapeutics Adds $15 Million in Capital to Expedite Development of Pain Treatment Drugs
Marketwired - Wed Oct 29, 8:08AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a biopharmaceutical firm with four novel pain treatment drugs currently under development in its pipeline, received a healthy injection of more than $15 million in capital last week that will assist the company in the advancement of its work to bring those products to the largest drug prescription market in the world - the treatment of pain.
Relmada Therapeutics Reinforces Balance Sheet With $15.2 Million From Exercise Of Warrants
PR Newswire - Thu Oct 16, 7:00AM CDT
Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today the issuance of approximately 10.1 million of its shares of common stock pursuant to the exercise of A-Warrants originally issued in connection with private placements that closed in May and June 2014. The warrants were exercised at $1.50 per share, resulting in gross proceeds of approximately $15.2M for the Company.
New Report Initiates Coverage on New Public Biopharmaceutical Company, Relmada Therapeutics, Inc.
Marketwired - Thu Oct 09, 8:16AM CDT
After careful analysis, Stock Market Media Group (SMMG), a research and content development IR firm, announces that it has initiated coverage on Relmada Therapeutics, Inc. (OTCQB: RLMD), a biopharmaceutical firm with 4 novel drugs currently in its pipeline under development. In a new Report, SMMG examines the company's unique drug development strategy, its pipeline of drugs for the treatment of pain, the multi-billion dollar market in which the biotech's products will compete, and both the impressive management team and Scientific Advisory Board that will lead the firm into the future.
Relmada Therapeutics names Julie J. Chen as director of Finance and Operations to strengthen financial and business operations
M2 - Fri Oct 03, 4:35AM CDT
Pharmaceutical company Relmada Therapeutics (OTC BB :RLMD) reported on Thursday the addition of Julie J. Chen as director of its Finance and Operations.
Relmada Therapeutics Appoints Julie J. Chen As Director of Finance and Operations
PR Newswire - Thu Oct 02, 7:15AM CDT
Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Julie J. Chen as its Director of Finance and Operations.
Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development
PR Newswire - Thu Sep 18, 6:45AM CDT
Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Mr. Christopher W. James to the position of Senior Director of Clinical Development.
Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER
PR Newswire - Tue Sep 16, 6:45AM CDT
Relmada Therapeutics, Inc., (OTCBB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has entered into an agreement with Memorial Sloan Kettering Cancer Center (MSKCC) in a series of animal studies for levorphanol, the active ingredient of LevoCap ER, a new tamper-resistant, extended release form of levorphanol. Gavril Pasternak, MD, PhD, of MSKCC is the lead investigator for these studies.
Relmada Announces The Filing Of Clinical Trial Application In Canada For d-methadone
PR Newswire - Wed Sep 10, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCBB: RLMD) ("Relmada" or the "Company"
, a clinical stage company developing novel therapies for the treatment of chronic pain, today announced that it has filed a Clinical Trial Application (CTA) with Heath Canada to conduct 2 pharmacokinetic studies with d-methadone, its NMDA receptor antagonist for neuropathic pain. Health Canada has accepted the application that is now under review.
Relmada Therapeutics, Inc. Provides Its First Corporate Update as a Public Company
PR Newswire - Tue Sep 09, 7:15AM CDT
Relmada Therapeutics, Inc., (OTCBB: RLMD), a Nevada corporation (the "Company" developing novel therapies for the treatment of chronic pain, today announced that is has filed its Form 10-K with the SEC, showing the Company's significant strides in 2014. The Company has made significant progress scientifically, financially and structurally in the implementation of its business strategy and is pleased to provide its first corporate update as a public company.
Opium (Opioid) Addiction - Pipeline Review, H2 2014 - 19 Drug Profiles from 13 Companies
M2 - Tue Sep 09, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/76t4hq/opium_opioid) has announced the addition of the "Opium (Opioid) Addiction - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alkermes Plc - Nanotherapeutics, Inc. - Acura Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - INSYS Therapeutics, Inc. - Camurus AB - Omeros Corporation - D&A Pharma SAS - Reckitt Benckiser Pharmaceutical, Inc. - AllTranz, Inc. - Relmada Therapeutics, Inc. - Celtic Pharmaceutical Holdings L.P. - Foresee Pharmaceuticals, LLC Drug Profiles - TA-CD - buprenorphine hydrochloride - RBP-6300 - Cannabidiol - OMS-405 - MAL - samidorphan - (buprenorphine hydrochloride naloxone hydrochloride) - CPP-115 - OMS-527 - buprenorphine hydrochloride ER - Vaccine for Opium Addiction - Cannabidiol - FP-004 - methadone IR - buprenorphine hydrochloride - Synthetic Peptides to Activate DOR and MOR and Inhibit MRP-1 for Oncology and Morphine Addiction - Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - naltrexone For more information visit http://www.researchandmarkets.com/research/76...ium_opioid
INSY: 38.57 (-0.14), CPRX: 2.66 (-0.17), ALKS: 51.47 (-1.75), ACUR: 0.51 (-0.05), OMER: 18.98 (-0.59)
Relmada Therapeutics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2014
PR Newswire - Wed Sep 03, 6:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or the "Company" , today announced it will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2014, at The Palace Hotel in New York City.
Relmada Therapeutics, Inc. Completes Name Change and Announces New Ticker
PR Newswire - Wed Aug 06, 9:01AM CDT
Relmada Therapeutics, Inc., (OTCBB: RLMD), a Nevada corporation (the "Company" , a clinical-stage company developing novel therapies for the treatment of chronic pain is pleased to announce that Financial Industry Regulatory Authority (FINRA) has approved the Company's application for a name change from Camp Nine, Inc. to Relmada Therapeutics, Inc. and assigned a new trading symbol, RLMD.
Relmada Therapeutics hires Michael Becker as SVP of finance and corporate development to broaden and strengthen its senior leadership team
M2 - Wed Nov 05, 6:31AM CST
Biopharmaceutical company Relmada Therapeutics (OtherOTC:RLMD) disclosed on Tuesday the election of Michael D. Becker as senior vice president of its finance and corporate development with immediate effect.
Relmada Therapeutics Appoints Michael Becker As Senior Vice President Of Finance And Corporate Development
PR Newswire - Tue Nov 04, 7:00AM CST
Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Michael D. Becker as senior vice president of finance and corporate development, effective immediately.
Relmada Therapeutics Adds $15 Million in Capital to Expedite Development of Pain Treatment Drugs
Marketwired - Wed Oct 29, 8:08AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a biopharmaceutical firm with four novel pain treatment drugs currently under development in its pipeline, received a healthy injection of more than $15 million in capital last week that will assist the company in the advancement of its work to bring those products to the largest drug prescription market in the world - the treatment of pain.
Relmada Therapeutics Reinforces Balance Sheet With $15.2 Million From Exercise Of Warrants
PR Newswire - Thu Oct 16, 7:00AM CDT
Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today the issuance of approximately 10.1 million of its shares of common stock pursuant to the exercise of A-Warrants originally issued in connection with private placements that closed in May and June 2014. The warrants were exercised at $1.50 per share, resulting in gross proceeds of approximately $15.2M for the Company.
New Report Initiates Coverage on New Public Biopharmaceutical Company, Relmada Therapeutics, Inc.
Marketwired - Thu Oct 09, 8:16AM CDT
After careful analysis, Stock Market Media Group (SMMG), a research and content development IR firm, announces that it has initiated coverage on Relmada Therapeutics, Inc. (OTCQB: RLMD), a biopharmaceutical firm with 4 novel drugs currently in its pipeline under development. In a new Report, SMMG examines the company's unique drug development strategy, its pipeline of drugs for the treatment of pain, the multi-billion dollar market in which the biotech's products will compete, and both the impressive management team and Scientific Advisory Board that will lead the firm into the future.
Relmada Therapeutics names Julie J. Chen as director of Finance and Operations to strengthen financial and business operations
M2 - Fri Oct 03, 4:35AM CDT
Pharmaceutical company Relmada Therapeutics (OTC BB :RLMD) reported on Thursday the addition of Julie J. Chen as director of its Finance and Operations.
Relmada Therapeutics Appoints Julie J. Chen As Director of Finance and Operations
PR Newswire - Thu Oct 02, 7:15AM CDT
Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Julie J. Chen as its Director of Finance and Operations.
Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development
PR Newswire - Thu Sep 18, 6:45AM CDT
Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Mr. Christopher W. James to the position of Senior Director of Clinical Development.
Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER
PR Newswire - Tue Sep 16, 6:45AM CDT
Relmada Therapeutics, Inc., (OTCBB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has entered into an agreement with Memorial Sloan Kettering Cancer Center (MSKCC) in a series of animal studies for levorphanol, the active ingredient of LevoCap ER, a new tamper-resistant, extended release form of levorphanol. Gavril Pasternak, MD, PhD, of MSKCC is the lead investigator for these studies.
Relmada Announces The Filing Of Clinical Trial Application In Canada For d-methadone
PR Newswire - Wed Sep 10, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCBB: RLMD) ("Relmada" or the "Company"
, a clinical stage company developing novel therapies for the treatment of chronic pain, today announced that it has filed a Clinical Trial Application (CTA) with Heath Canada to conduct 2 pharmacokinetic studies with d-methadone, its NMDA receptor antagonist for neuropathic pain. Health Canada has accepted the application that is now under review. Relmada Therapeutics, Inc. Provides Its First Corporate Update as a Public Company
PR Newswire - Tue Sep 09, 7:15AM CDT
Relmada Therapeutics, Inc., (OTCBB: RLMD), a Nevada corporation (the "Company"
developing novel therapies for the treatment of chronic pain, today announced that is has filed its Form 10-K with the SEC, showing the Company's significant strides in 2014. The Company has made significant progress scientifically, financially and structurally in the implementation of its business strategy and is pleased to provide its first corporate update as a public company. Opium (Opioid) Addiction - Pipeline Review, H2 2014 - 19 Drug Profiles from 13 Companies
M2 - Tue Sep 09, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/76t4hq/opium_opioid) has announced the addition of the "Opium (Opioid) Addiction - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alkermes Plc - Nanotherapeutics, Inc. - Acura Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - INSYS Therapeutics, Inc. - Camurus AB - Omeros Corporation - D&A Pharma SAS - Reckitt Benckiser Pharmaceutical, Inc. - AllTranz, Inc. - Relmada Therapeutics, Inc. - Celtic Pharmaceutical Holdings L.P. - Foresee Pharmaceuticals, LLC Drug Profiles - TA-CD - buprenorphine hydrochloride - RBP-6300 - Cannabidiol - OMS-405 - MAL - samidorphan - (buprenorphine hydrochloride naloxone hydrochloride) - CPP-115 - OMS-527 - buprenorphine hydrochloride ER - Vaccine for Opium Addiction - Cannabidiol - FP-004 - methadone IR - buprenorphine hydrochloride - Synthetic Peptides to Activate DOR and MOR and Inhibit MRP-1 for Oncology and Morphine Addiction - Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - naltrexone For more information visit http://www.researchandmarkets.com/research/76...ium_opioid
INSY: 38.57 (-0.14), CPRX: 2.66 (-0.17), ALKS: 51.47 (-1.75), ACUR: 0.51 (-0.05), OMER: 18.98 (-0.59)
Relmada Therapeutics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2014
PR Newswire - Wed Sep 03, 6:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or the "Company"
, today announced it will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2014, at The Palace Hotel in New York City. Relmada Therapeutics, Inc. Completes Name Change and Announces New Ticker
PR Newswire - Wed Aug 06, 9:01AM CDT
Relmada Therapeutics, Inc., (OTCBB: RLMD), a Nevada corporation (the "Company"
, a clinical-stage company developing novel therapies for the treatment of chronic pain is pleased to announce that Financial Industry Regulatory Authority (FINRA) has approved the Company's application for a name change from Camp Nine, Inc. to Relmada Therapeutics, Inc. and assigned a new trading symbol, RLMD. 
